Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
Follow SCLX
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more quarters Free account |
10.56 | 4.79 | 8.61 | 7.64 |
Revenue Growth |
(26.85%) | (67.83%) | 72.12% | (22.78%) | |
Cost of Revenue |
3.33 | 2.61 | 4.45 | 3.68 | |
Gross Profit |
7.23 | 2.18 | 4.17 | 3.97 | |
R&D Expenses |
3.90 | 8.17 | 3.21 | 3.34 | |
SG&A Expenses |
188.82 | 30.16 | 31.03 | 27.96 | |
Operating Income |
(186.51) | (111.09) | (32.17) | (29.42) | |
Non-operating Interest Expenses |
2.80 | 5.98 | — | 6.10 | |
Non-operating Income/Expense |
(71.31) | 65.00 | (13.48) | (85.57) | |
| (257.82) | (46.10) | (45.65) | (114.98) | ||
Income Tax Provision |
0.00 | 0.01 | — | 0.01 | |
Income after Tax |
(257.82) | (46.10) | (45.65) | (114.99) | |
Dividends (Preferred) |
— | — | — | 1.23 | |
Non-Controlling Interest |
(0.59) | (12.99) | (2.38) | (1.49) | |
Net Income Common |
(257.23) | (33.11) | (43.27) | (114.73) | |
EPS (Basic) |
(22.17) | (4.60) | (6.28) | (16.65) | |
EPS (Diluted) |
(22.17) | (4.60) | (6.28) | (16.65) | |
Shares (Basic, Weighted) |
11.60 | 11.03 | 6.89 | 6.89 | |
Shares (Diluted, Weighted) |
11.60 | 11.03 | 6.89 | 6.89 | |
Gross Margin |
68.48% | 45.46% | 48.37% | 51.88% | |
EBIT Margin |
(1,766.21%) | (2,317.76%) | (373.49%) | (385.02%) | |
EBT margin |
(2,441.47%) | (961.80%) | (530.01%) | (1,504.57%) | |
Net Profit Margin |
(2,435.93%) | (690.84%) | (502.38%) | (1,501.30%) | |
EBITDA |
(185.49) | (35.74) | (28.27) | (25.60) | |
EBIT |
(186.51) | (111.09) | (32.17) | (29.42) | |
Income from Continuous Operations |
(257.82) | (46.10) | (45.65) | (114.99) | |
Consolidated Net Income/Loss |
(257.82) | (46.10) | (45.65) | (114.99) | |
EPS (Basic, from Continuous Ops) |
(22.22) | (5.63) | (6.62) | (16.68) | |
EPS (Diluted, from Cont. Ops) |
(22.22) | (5.63) | (6.62) | (16.68) | |
EPS (Basic, Consolidated) |
(22.22) | (5.63) | (6.62) | (16.68) | |
EPS (Diluted, Consolidated) |
(22.22) | (5.63) | (6.62) | (16.68) | |
Shares (Diluted, Average) |
11.60 | 11.03 | 6.89 | 6.89 | |
EBITDA Margin |
(1,756.52%) | (745.59%) | (328.25%) | (334.95%) | |
Operating Cash Flow Margin |
77.94% | (364.51%) | (12.85%) | (88.16%) |